[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  BowTiedBiotech 🧪🔬🧬 [@BowTiedBiotech](/creator/twitter/BowTiedBiotech) on x 19.7K followers Created: 2024-08-16 14:44:47 UTC Tale of Woe for Pharma CROs "Since January, hardship has hit the preclinical contract research labs - Evotec, Wuxi Apptec, and Gingko Bioworks. All down XX% to XX% in this short time span. Charles River still holding stable. " "Surprising that Wuxi Apptec, even with the highly publicized headwinds, still outperformed Evotec and Gingko, which have their own set of problems." "In what appears to be a disaster year for the contract research lab industry, this massive drop in share price appears to be correlated with the general retraction of big pharma headcount and layoffs. Fewer orders placed, less revenue, less research done. Hopefully this will not turn into a vicious cycle." Source: Vincent Ling on the HR app  XXXXX engagements  **Related Topics** [$2359hk](/topic/$2359hk) [$evtde](/topic/$evtde) [Post Link](https://x.com/BowTiedBiotech/status/1824457282647658601)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
BowTiedBiotech 🧪🔬🧬 @BowTiedBiotech on x 19.7K followers
Created: 2024-08-16 14:44:47 UTC
Tale of Woe for Pharma CROs
"Since January, hardship has hit the preclinical contract research labs - Evotec, Wuxi Apptec, and Gingko Bioworks. All down XX% to XX% in this short time span. Charles River still holding stable. "
"Surprising that Wuxi Apptec, even with the highly publicized headwinds, still outperformed Evotec and Gingko, which have their own set of problems."
"In what appears to be a disaster year for the contract research lab industry, this massive drop in share price appears to be correlated with the general retraction of big pharma headcount and layoffs. Fewer orders placed, less revenue, less research done. Hopefully this will not turn into a vicious cycle."
Source: Vincent Ling on the HR app
XXXXX engagements
/post/tweet::1824457282647658601